Compare RLYB & DFLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLYB | DFLI |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.6M | 49.0M |
| IPO Year | 2021 | N/A |
| Metric | RLYB | DFLI |
|---|---|---|
| Price | $8.25 | $2.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 89.8K | ★ 466.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $858,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $51.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.00 | N/A |
| 52 Week Low | $0.24 | $0.15 |
| 52 Week High | $11.49 | $5.15 |
| Indicator | RLYB | DFLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 46.39 |
| Support Level | $7.90 | $0.21 |
| Resistance Level | $9.25 | $2.28 |
| Average True Range (ATR) | 0.50 | 0.18 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 29.74 | 71.21 |
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.